Feasibility ex vivo Homologous Recombination Deficiency (HRD) test in advanced breast cancer disease: a pilot study
Completed
- Registration Number
- NL-OMON24673
- Lead Sponsor
- Erasmus MC, Cancer Institute, department of Medical Oncology, Rotterdam.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
• The site of the tumor should be amendable for biopsy. NB lung metastases (high risk of hematothorax) and bone metastases (not suitable for ex vivo test because calcifications interfere with experimental procedures) are excluded.
• Age >18 years
Exclusion Criteria
Current therapeutically use of anti-coagulant (coumarin derivates, warfarin, heparin or low molecular weight heparin [LMWH]) whereby a short interruption of drug use is not allowed. LMWH if used for prophylaxis is allowed.
• Any psychological condition potentially hampering compliance with the study protocol
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the proportion of patients with a useful test result (Putest)<br>will be considered as the primary end point
- Secondary Outcome Measures
Name Time Method